Immunovant (IMVT) Receivables (2021 - 2026)

Immunovant has reported Receivables for 6 years, with the latest figure at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 45.63% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 45.63% YoY), and the FY2026 full-year result was $1.1 million, down 45.63% from the prior year.
• Receivables for Q1 2026 stood at $1.1 million, down from $1.6 million in the prior quarter.
• The five-year high for Receivables was $13.2 million in Q2 2022, with the low at $700000.0 in Q1 2023.
• Historically, Receivables has averaged $3.2 million across 5 years, with a median of $1.9 million in 2025.
• Annual changes were most pronounced in 2022 — Receivables surged 1951.85% — and 2023, when it sank 94.28%.
• Immunovant's Receivables stood at $704000.0 in 2022, then jumped by 46.16% to $1.0 million in 2023, then surged by 116.13% to $2.2 million in 2024, then declined by 26.12% to $1.6 million in 2025, then slumped by 31.04% to $1.1 million in 2026.
• The last three Receivables figures came in at $1.1 million (Q1 2026), $1.6 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.